Changes are underway…

In December 2024, Rhythm Biosciences (ASX:RHY), a medical technology company transforming cancer diagnostics through innovative diagnostic technologies that predict, detect, characterise, and support early intervention, acquired the geneType™ business assets.

Business integration is currently in progress expected to be completed by 1HCY25.

Investors should visit the Rhythm Biosciences website for more information.